IP Library Granted Patent US 11,324,696
Granted Patent B2
US 11,324,696 · App. 17/133,415 · Granted May 10, 2022

Suspensions and diluents for metronidazole and baclofen

Inventors: Ken Fallin (Diamondhead, MS); Zeus Pendon (Woburn, MA); Priya Capila (Wellesley, MA); Neal Muni (Wellesley, MA)
Assignee: AZURITY PHARMACEUTICALS, INC.
A61K9/10A61K9/0095A61K31/197A61K31/4164A61K47/12A61K47/26A61K47/34A61K47/36A61K47/38A61K47/46A61P31/04A61P33/02Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,324,696
App. No.
17/133,415
Granted
May 10, 2022
Kind
B2
Abstract

Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension my include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water.

Claims (19)

1. A liquid pharmaceutical composition that comprises:

a) 5 mg/ml of baclofen or a salt thereof;

b) 0.12% (w/v) of citric acid (anhydrous);

c) 0.5% (w/v) of hydroxyethyl cellulose;

d) 5% (w/v) of propylene glycol;

e) 0.15% (w/v) of simethicone emulsion (30%);

f) 0.1% (w/v) of sodium benzoate;

g) 0.2% (w/v) of sucralose; and

h) water,

wherein a pH of the pharmaceutical composition is between 3.0 and 6.0, and

wherein the pharmaceutical composition retains less than +/−5% variation of baclofen concentration measured by a USP assay for at least 30 days when stored at room temperature.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further retains less than +/−5% variation of baclofen concentration measured by a USP assay for at least 30 days when stored at 38-42° C.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further retains less than +/−5% variation of baclofen concentration measured by a USP assay for at least 30 days when stored at 15-30° C.

4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises a coloring agent, a flavoring agent, or a combination thereof.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 0.0002% (w/v) of D&C Yellow No. 10.

6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 0.000038% (w/v) of FD&C Red No. 40.

7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 0.0500% (w/v) of flavor grape 59.266/A.

8. The pharmaceutical composition of claim 1 , wherein the pH of the pharmaceutical composition is about 3.6 to 4.6.

9. The pharmaceutical composition of claim 1 , wherein the pH of the pharmaceutical composition is about 4.0 to 4.3.

Assignments (7)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 057531/0403 →
SECURITY INTEREST Recorded Sep 20, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057532/0424 →
SECURITY INTEREST Recorded Apr 16, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 055938/0859 →
CHANGE OF NAME Recorded Jan 8, 2021
From: CUTISPHARMA, INC.
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 054942/0713 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2021
From: FALLIN, KEN; PENDON, ZEUS; CAPILA, PRIYA; MUNI, NEAL
To: CUTISPHARMA, INC.
Reel/Frame 054861/0298 →
Continuity (3)
Continuation 16331733
Provisional Application 62385325 · Sep 9, 2016
Related Publication 20210220267A1 · Jul 22, 2021
Cited By (1)
US 12,458,593